SAB Biotherapeutics Files 8-K: Agreements, Equity Sales, Bylaw Changes
Ticker: SABSW · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Jul 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, corporate-action
TL;DR
SAB Biotherapeutics filed an 8-K on 7/21/25 covering new deals, stock sales, and bylaw updates.
AI Summary
On July 21, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing several events. These include entering into a material definitive agreement, unregistered sales of equity securities, and amendments to its articles of incorporation or bylaws. The company, formerly known as Big Cypress Acquisition Corp., is involved in biological products.
Why It Matters
This filing indicates significant corporate actions by SAB Biotherapeutics, including potential new agreements and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 001-39871 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-3899721 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former company name
- July 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific material definitive agreement did SAB Biotherapeutics enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities, but the specific type and terms are not detailed in the provided text.
What amendments were made to the articles of incorporation or bylaws?
The filing notes amendments to articles of incorporation or bylaws, but the exact nature of these changes is not specified in the excerpt.
When did SAB Biotherapeutics change its name from Big Cypress Acquisition Corp.?
SAB Biotherapeutics, Inc. changed its name from Big Cypress Acquisition Corp. on November 20, 2020.
What is the primary business of SAB Biotherapeutics, Inc.?
SAB Biotherapeutics, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding SAB Biotherapeutics, Inc. (SABSW).